

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older ID6542

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Rhythm Pharmaceuticals (setmelanotide) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • All About Obesity • Astro Brain Tumour Fund • Blood Pressure UK • Brain and Spine Foundation • Brain Tumour Charity • Brainstrust • British Brain Tumour Association • British Obesity Society • Cardiomyopathy UK • Cardiovascular Care Partnership • Circulation Foundation • Diabetes UK • HEART UK • Kidney Care UK • Kidney Research UK • National Kidney Federation • Network of Sikh Organisations • Neurological Alliance • Obesity Empowerment Network • Obesity Health Alliance • Obesity UK • Pumping Marvellous Foundation • Somerville Heart Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Stroke Association • Stroke Information • The Brain Charity 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health - Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • NHS Wales Joint Commissioning Committee • Scottish Medicines Consortium • Welsh Government <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Biocon Pharma UK (liraglutide) • Cipla EU (liraglutide) • Eli Lilly (tirzepatide) • Haeon UK (orlistat) • Neon Healthcare (orlistat) • Novo Nordisk (semaglutide, liraglutide) • Ranbaxy UK (liraglutide) • Zentiva (liraglutide)

Provisional stakeholder list for the evaluation of setmelanotide for treating acquired hypothalamic obesity in people 4 years and older ID6542

Issue date: January 2026

© National Institute for Health and Care Excellence 2026. All rights reserved.

1 of 4

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> Weight Concern <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> Association for the Study of Obesity Association of British Neurologists British and Irish Association of Stroke Physicians British and Irish Hypertension Society British Association for Nursing in Cardiovascular Care British Association of Head and Neck Oncologists British Association of Head and Neck Oncology Nurses British Cardiovascular Society British Dietetic Association British Geriatrics Society British Heart Foundation British Heart Rhythm Society British Nutrition Foundation British Obesity & Metabolic Surgery Society British Skull Base Society British Society for Haemostasis and Thrombosis British Society for Heart Failure British Society for Paediatric Endocrinology and Diabetes Clinical Leaders of Thrombosis (CLOT) Faculty of Public Health National Heart and Lung Institute National Neuroscience Advisory Group Neonatal and Paediatric Pharmacists Group Nutrition Society Obesity Management Association Obesity Management Collaborative Obesity Specialist Group (BDA) Primary Care Cardiovascular Society Royal College of Emergency Medicine Royal College of General Practitioners 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> Brain Tumour Research Brain Tumour Research Campaign British Society for Cardiovascular Research [BCS affiliated] Cochrane Heart, Stroke and Circulation Cochrane Metabolic & Endocrine Disorders Group Cochrane Public Health Group European Council for Cardiovascular Research Genomics England Heart Research UK Institute of Neurology MRC Clinical Trials Unit National Centre for Cardiovascular Preventions and Outcomes National Institute for Health Research Oracle Cancer Trust Tessa Jowell Brain Cancer Mission Wellcome Trust <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> Public Health Wales UK Health Security Agency

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science and Technology • Society for Endocrinology • Society for Vascular Nurses • Society for Vascular Technology • Society of British Neurological Surgeons • UK Clinical Pharmacy Association • Vascular Society of Great Britain and Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • Great Ormond Street Hospital Metabolic Unit • NHS England • Salford Royal NHS Foundation Trust Mark Holland Metabolic Unit • University College London Hospital Charles Dent Metabolic Unit • University Hospital Birmingham Foundation Trust, Department of Endocrinology 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.